Literature DB >> 7544458

Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction.

M A Martínez1, M Sala, J P Vartanian, S Wain-Hobson.   

Abstract

G-->A hypermutation is a remarkable phenomenon resulting from retroviral reverse transcription in the presence of highly biased dNTP concentrations. Of the three reverse transcriptases (RTases) available, those of human immunodeficiency virus type 1 (HIV-1), avian myeloblastosis virus (AMV) and Moloney murine leukemia virus (MoMLV), the HIV-1 enzyme showed the greatest sensitivity to biased [dCTP]/[dTTP] ratios. The HIV-1 RTase was able to discriminate between dUTP, dITP and the four DNA precursors and was insensitive to pH. There was little preference for nucleotide contexts. A few exceptionally modified sequences were found presumably resulting from G-->A hypermutation and multiple strand transfer. This particular predilection of the HIV-1 and, by extrapolation, the lentiviral RTases towards G-->A hypermutation suggests that the phenomenon may have contributed to the remarkably elevated A content of these retroviral genomes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544458      PMCID: PMC307076          DOI: 10.1093/nar/23.14.2573

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  22 in total

1.  Template switching by reverse transcriptase during DNA synthesis.

Authors:  G X Luo; J Taylor
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Human infection by genetically diverse SIVSM-related HIV-2 in west Africa.

Authors:  F Gao; L Yue; A T White; P G Pappas; J Barchue; A P Hanson; B M Greene; P M Sharp; G M Shaw; B H Hahn
Journal:  Nature       Date:  1992-08-06       Impact factor: 49.962

3.  A constant rate of spontaneous mutation in DNA-based microbes.

Authors:  J W Drake
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

4.  The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques.

Authors:  P R Johnson; T E Hamm; S Goldstein; S Kitov; V M Hirsch
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 5.  DNA mismatch correction.

Authors:  P Modrich
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

6.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes.

Authors:  J P Vartanian; A Meyerhans; B Asjö; S Wain-Hobson
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Requirements for strand transfer between internal regions of heteropolymer templates by human immunodeficiency virus reverse transcriptase.

Authors:  J J DeStefano; L M Mallaber; L Rodriguez-Rodriguez; P J Fay; R A Bambara
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

9.  5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate.

Authors:  V K Pathak; H M Temin
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  How the structure of an adenine tract depends on sequence context: a new model for the structure of TnAn DNA sequences.

Authors:  M A Price; T D Tullius
Journal:  Biochemistry       Date:  1993-01-12       Impact factor: 3.162

View more
  11 in total

1.  The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

2.  Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication.

Authors:  T Kim; R A Mudry; C A Rexrode; V K Pathak
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Three-Dimensional Visualizations in Teaching Genomics and Bioinformatics: Mutations in HIV Envelope Proteins and Their Consequences for Vaccine Design.

Authors:  Kathy M Takayama
Journal:  Microbiol Educ       Date:  2004-05

4.  Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.

Authors:  J Balzarini; M J Camarasa; M J Pérez-Pérez; A San-Félix; S Velázquez; C F Perno; E De Clercq; J N Anderson; A Karlsson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.

Authors:  M Janini; M Rogers; D R Birx; F E McCutchan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Stably expressed APOBEC3F has negligible antiviral activity.

Authors:  Eri Miyagi; Charles R Brown; Sandrine Opi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Robert C Walker; Vanessa Hirsch; Klaus Strebel
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

7.  Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions.

Authors:  J P Vartanian; M Henry; S Wain-Hobson
Journal:  Nucleic Acids Res       Date:  1996-07-15       Impact factor: 16.971

8.  Fate of direct and inverted repeats in the RNA hypermutagenesis reaction.

Authors:  V Pezo; M A Martinez; S Wain-Hobson
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

9.  Exploring the functional robustness of an enzyme by in vitro evolution.

Authors:  M A Martinez; V Pezo; P Marlière; S Wain-Hobson
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

10.  Increased G-->A transition frequencies displayed by primer grip mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Clara E Cases-González; Luis Menéndez-Arias
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.